

## Join Global Leaders in Shaping the Future of Drug Development at C-Path's 2025 Global Impact Conference

*Every Stage, Every Step: Transforming Lives Through Optimized Drug Development*

**TUCSON**, Ariz., July 22, 2025 — Stakeholders across the life sciences ecosystem are invited to attend the 2025 Critical Path Institute® (C-Path) [Global Impact Conference \(CGIC\)](#), taking place Sept. 9–11 at the Washington Marriott at Metro Center in Washington, D.C.

CGIC 2025 is where the drug development community comes together to connect, collaborate, and spark solutions that drive progress in neurology, rare diseases, pediatrics, and beyond, through the transformation of data into actionable and clinically meaningful knowledge. Held during C-Path's milestone 20th anniversary year, the conference will feature cross-sector networking, dynamic discussions, and real-world examples of how public-private partnerships are advancing patient-focused innovation around the world.

“C-Path's Global Impact Conference is where ideas become action,” said C-Path CEO Klaus Romero, M.D., M.S., FCP. “CGIC 2025 will not only highlight the scientific and regulatory advances that are reshaping drug development globally, but also celebrate the partnerships that have made it possible. This year's event represents a unique opportunity to connect the dots across therapeutic areas and identify where we go next — together.”

Attendees will hear from confirmed speakers representing leading organizations such as the European Medicines Agency, Japan's PMDA/NCCHD and the U.S. Food and Drug Administration; nonprofits including Breakthrough T1D, FasterCures, Milken Institute, and UnshakableMD; and pharmaceutical and industry leaders such as Biogen, Consilium Salmonson & Hemmings, Eisai, Johnson & Johnson, Revalia Bio, Sanofi, and Takeda. Academic and clinical institutions like Harvard Medical School and Mayo Clinic will also be represented—each bringing valuable expertise and perspective to the conversations that will help define the future of medical innovation.

Over two and a half days, CGIC 2025 will feature sessions on today's most pressing challenges in drug development. The event will include:

- Cross-sector networking opportunities



- Expert-led panels and case studies
- Tools, resources and collaborative approaches designed to address real-world challenges in drug development

Participants from industry, regulatory agencies, academia, patient advocacy groups and those with lived experience will find CGIC 2025 an invaluable space to exchange insights and engage in meaningful dialogue around the future of medical innovation.

“At The Michael J. Fox Foundation, we’ve set out to help drug developers enable novel therapeutic approaches to get treatments into patient hands. In practice, this requires cross-collaboration to spearhead solutions around seemingly intractable field-wide challenges,” said Catherine Kopil, Ph.D., Senior Vice President of Clinical Research at The Michael J. Fox Foundation. “Joining leaders at C-Path’s 2025 Global Impact Conference brings together regulators and drug developers from across therapeutic areas to engage in open, science-based dialogue. That kind of cross-sector collaboration is essential for moving the field forward in ways that truly reflect the unmet needs of patients and families.”

Registration for CGIC 2025 is now open, [here](#). To learn more about the conference, agenda, speakers, and travel information, visit the event page, [here](#).

### **About Critical Path Institute**

Founded in 2005, as a public-private partnership in response to the [FDA’s Critical Path Initiative](#), Critical Path Institute® (C-Path) celebrates its 20th anniversary as a vital, independent, nonprofit. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit [c-path.org](https://c-path.org).

Critical Path Institute is supported by the Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS) and is 56% funded by the FDA/HHS, totaling \$23,740,424, and 44% funded by non-government source(s), totaling \$18,881,611. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.

### **Media Contacts:**

Roxan Triolo Olivas  
C-Path  
520.954.1634  
[rolivas@c-path.org](mailto:rolivas@c-path.org)

Kissy Black  
C-Path  
615.310.1894  
[kblack@c-path.org](mailto:kblack@c-path.org)